Reinsurance Group of America Beats Q3 2026 Estimates as Revenue Rises 21% to $7.55B
Revenue of $7.55B vs. $6.69B expected and adjusted EPS of $8.49 vs. $6.97; revenue up 21% from a year earlier.
Reinsurance Group of America (RGA) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $7.55 billion, up 21% from a year earlier, above the $6.69 billion estimate, and adjusted EPS was $8.49, up 33% from a year earlier, above the $6.97 estimate.
Shares rose 0.7% in after-hours trading as of 4:15 p.m. ET, to $263.80 from a $261.96 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $6.97 | $8.49 | Beat by 22% |
| Revenue | $6.69B | $7.55B | Beat by 13% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 33% | ▼ 4.5% |
| Revenue | ▲ 21% | ▲ 14% |
By our calculation, revenue was $861.5 million above the estimate and adjusted EPS was $1.52 above it. The QoQ column compares with the previous quarter's revenue of $6.64 billion and adjusted EPS of $8.89. The YoY column compares with $6.23 billion and $6.37 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $6.23 billion, $6.63 billion, $6.49 billion, $6.64 billion and $7.55 billion.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $7.02 and revenue of $6.88 billion next quarter, based on 6 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 21% increase to $7.55 billion.
- Estimate record. Whether Reinsurance Group of America extends a record of beating EPS estimates in 6 of its last 8 reports.
- Related coverage. See our reports on Genmab A/S, Protagonist Therapeutics, Fidelity National Financial and Camden Property Trust.
Sources: Results are from Reinsurance Group of America's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Reinsurance Group of America's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Genmab A/S Q3 2026 EPS Tops Estimates at $0.56, but Revenue Misses at $1.19B
EarningsProtagonist Therapeutics Beats Q3 2026 Estimates as Revenue Rises 5724% to $274.4M
EarningsFidelity National Financial Falls Short of Q3 2026 Estimates as Revenue Falls 9.2% to $3.58B
EarningsCamden Property Trust Misses Q3 2026 Estimates as Revenue Falls 3.7% to $381.1M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
